Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA
12. März 2024 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
REYKJAVIK, Iceland and FORT WORTH, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Arctic Therapeutics ehf, an Icelandic drug development company and partner Nacuity Pharmaceuticals, Inc., a...
Next Generation Sequencing Market To Reach USD 19.12 Billion By 2026 | Reports And Data
18. September 2019 13:34 ET
|
Reports and Data
New York, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Government initiatives for large scale NGS based projects, collaborations for technical advancements in NGS and declining costs are key factors...
New Life Scientific, Inc. to Present at the ValueRich Small Cap Financial Exposition -- September 15, 2005
01. September 2005 06:20 ET
|
New Life Scientific Inc.
FREEHOLD, N.J., Sept. 1, 2005 (PRIMEZONE) -- New Life Scientific, Inc. ("New Life") (OTCBB:NWLF) www.newlifesci.com, an emerging bio-tech company, today announced that it will be a presenting company...
SmallCap Sentinel: Gauging the Impact of the Pending Horde of Baby Boomers
29. August 2005 03:30 ET
|
SmallCap Sentinel
IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "While many fear the lack of investment dollars in the stock market by retiring baby boomers, savvy investors are focusing on the areas where this...
Galapagos Announces Half Year 2005 Results
12. August 2005 02:24 ET
|
Galapagos Genomics
Mechelen, Belgium, Aug. 12, 2005 (PRIMEZONE) -- Galapagos:
- Financials on target for 2005 increased annual revenues and
cash burn of around 7 million euro
- Initial public offering...
Keryx Biopharmaceuticals to Present at Banc of America Securities Annual Health Care Conference
17. Mai 2005 08:29 ET
|
Keryx Biopharmaceuticals, Inc.
NEW YORK, May 17, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the...
Galapagos Appoints Andre Hoekema as Managing Director Galadeno
12. April 2005 05:07 ET
|
Crucell N.V.
LEIDEN, Netherlands, April 12, 2005 (PRIMEZONE) -- Galapagos, a genomics-based drug discovery company, has appointed Dr. Andre Hoekema as Managing Director of Galadeno, Galapagos' services unit....
Actelion Ltd: Japanese Approval for Tracleer(r) in PAH
11. April 2005 01:31 ET
|
Actelion Ltd.
ALLSCHWIL, Switerzerland, April 11, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval...
Crucell and DSM Announce PER.C6(R) Licensing and Service Agreement with Roche for Protein Production
16. Februar 2005 02:13 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Feb. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they...
Crucell Fully Compliant
26. Januar 2005 07:38 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Jan. 26, 2005 (PRIMEZONE) -- In media coverage today a suggestion was made that insider trading occurred on the exercise of options on January 18, 2005, by certain employees...